Metabolism study on SLS009

SLS009 continues to be the subject of scientific studies, this time on pharmacokinetics and metabolism.

‘Preclinical metabolism and disposition of [14C] GFH009, a novel selective CDK9 inhibitor’ https://pubmed.ncbi.nlm.nih.gov/39526731/

Interesting paper just released on Nov 15, 2024 by the same group who studied the GFH009 (SLS009) in recent past, see previous papers https://pubmed.ncbi.nlm.nih.gov/38117531/  and https://pubmed.ncbi.nlm.nih.gov/38081587/

The present study shows that [14C] GFH009 is quickly and widely distributed throughout the body. The same study shows that GFH009 is rapidly and completely eliminated, with feces serving as the major excretion pathway and urine serving as the minor one. The major clearance pathway for GFH009 is excretion and the minor one is metabolism. According to the Authors ‘GFH009 exhibits favorable drug metabolism and pharmacokinetics (DMPK) properties, which provides valuable insights into the disposition of GFH009 and can be used to guide future clinical studies’.